Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × capmatinib × 90 days × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Interventional 3 Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

Suspensions 2 Powders 2 venetoclax 1 ulixertinib 1 telisotuzumab vedotin 1 taletrectinib 1 selinexor 1 mifamurtide 1 futibatinib 1 dodecyl maltoside 1 capmatinib 1 asparaginase erwinia chrysanthemi recombinant 1 Taxes 1 Sunitinib 1 Peripheral Blood Stem Cell Transplantation 1 Paclitaxel 1 HMPL-013 1 Gemcitabine 1 Eflornithine 1 Docetaxel 1 Bone Marrow Transplantation 1 Asparaginase 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Novartis

No longer available

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡